Tandem Diabetes Care Inc Total Liabilities
Tandem Diabetes Care Inc total liabilities. Based on the latest financial reports, Tandem Diabetes Care Inc (TNDM) has total liabilities worth $1.02 Billion USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Tandem Diabetes Care Inc to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Tandem Diabetes Care Inc (2011–2025)
Total liabilities of Tandem Diabetes Care Inc from 2011 to 2025. This chart illustrates how Tandem Diabetes Care Inc's total liabilities have evolved over time, based on quarterly financial data. Explore TNDM long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Tandem Diabetes Care Inc Competitors by Total Liabilities
The table below lists competitors of Tandem Diabetes Care Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
RPC Inc
NYSE:RES
|
USA | $351.01 Million |
|
United States Steel Corp
BA:X
|
Argentina | AR$8.75 Billion |
|
Beijing Toread Outdoor Product
SHE:300005
|
China | CN¥1.25 Billion |
|
Gravita India Limited
NSE:GRAVITA
|
India | Rs9.59 Billion |
|
Sichuan Chengfei Integration Technology Corp Ltd
SHE:002190
|
China | CN¥2.40 Billion |
|
Ami Organics Limited
NSE:AMIORG
|
India | Rs2.29 Billion |
|
Inner Mongolia ERDOS Resources Co Ltd B
SHG:900936
|
China | $19.27 Billion |
|
TRUSTPILOT GROUP LS -01
F:6VZ
|
Germany | €134.24 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down Tandem Diabetes Care Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see TNDM asset base.
Liquidity & Leverage Metrics
Tandem Diabetes Care Inc Total Liabilities Ratios Explained
Tandem Diabetes Care Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.18 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 7.85 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.89 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tandem Diabetes Care Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tandem Diabetes Care Inc (2011–2025)
The table below shows the annual total liabilities of Tandem Diabetes Care Inc from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $725.94 Million | +3.03% |
| 2024-12-31 | $704.56 Million | +10.26% |
| 2023-12-31 | $639.03 Million | +4.27% |
| 2022-12-31 | $612.84 Million | +29.83% |
| 2021-12-31 | $472.02 Million | +34.82% |
| 2020-12-31 | $350.11 Million | +166.99% |
| 2019-12-31 | $131.13 Million | +74.80% |
| 2018-12-31 | $75.02 Million | -39.74% |
| 2017-12-31 | $124.49 Million | +5.22% |
| 2016-12-31 | $118.32 Million | +91.92% |
| 2015-12-31 | $61.65 Million | +18.81% |
| 2014-12-31 | $51.89 Million | +11.17% |
| 2013-12-31 | $46.68 Million | -68.00% |
| 2012-12-31 | $145.87 Million | +71.06% |
| 2011-12-31 | $85.27 Million | -- |
About Tandem Diabetes Care Inc
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and … Read more